Drugs / Iota-Carrageenan
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04701710 | Oct → Dec 2020 | COVID-19, severe acute respiratory syndrome | Maria de los Angeles Peral de Bruno | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT04521322 | Jul → Oct 2020 | COVID-19 | Ariel Dogliotti | Unknown | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03009799 Comparator | Jan → Aug 2017 | viral conjunctivitis | NicOx | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-02-19 | Marinomed Biotech AG | Results Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19 marinomed.com ↗
Marinomed Biotech AG (VSE:MARI) announces that a nasal spray with iota -carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with t his disease. |
| 2021-02-19 | Marinomed Biotech AG | Results Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19 marinomed.com ↗
Marinomed Biotech AG (VSE:MARI) announces that a nasal spray with iota-carrageenan, which is identical to Marinomed’s Carragelose®, showed significant efficacy in the prevention of COVID-19 in hospital staff who manage patients with this disease. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-19 | Marinomed Biotech AG | Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19 marinomed.com ↗ |
| 2021-02-19 | Marinomed Biotech AG | Marinomed Biotech AG shares positive clinical trial results for iota-carrageenan nasal spray in the prevention of COVID-19 marinomed.com ↗ |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Iota-Carrageenan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03009799 ↗ |
| Known as | I-C | “BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae, with demonstrated antiviral activity and clinical efficacy as nasal spray in the...” PMID 34629893 ↗ Oct 2021 |
| Action | Inhibit | “In vitro, I-C inhibits SARS-CoV-2 infection in cell culture.” PMID 34629893 ↗ Oct 2021 |
| Modality | Other / unclassified | “BACKGROUND: Iota-Carrageenan (I-C) is a sulfate polysaccharide synthesized by red algae” PMID 34629893 ↗ Oct 2021 |
| Route | Intranasal | “a nasal spray with I-C” PMID 34629893 ↗ Oct 2021 |